Cloning and Characterization of Trypanosoma congolense and T. vivax Nucleoside Transporters Reveal the Potential of P1-Type Carriers for the Discovery of Broad-Spectrum Nucleoside-Based Therapeutics against Animal African Trypanosomiasis
African Animal Trypanosomiasis (AAT), caused predominantly by Trypanosoma brucei brucei, T. vivax and T. congolense, is a fatal livestock disease throughout Sub-Saharan Africa. Treatment options are very limited and threatened by resistance. Tubercidin (7-deazaadenosine) analogs have shown activity against individual parasites but viable chemotherapy must be active against all three species. Divergence in sensitivity to nucleoside antimetabolites could be caused by differences in nucleoside transporters. Having previously characterized the T. brucei nucleoside carriers, we here report the functional expression and characterization of the main adenosine transporters of T. vivax (TvxNT3) and T. congolense (TcoAT1/NT10), in a Leishmania mexicana cell line ('SUPKO') lacking adenosine uptake. Both carriers were similar to the T. brucei P1-type transporters and bind adenosine mostly through interactions with N3, N7 and 3'-OH. Expression of TvxNT3 and TcoAT1 sensitized SUPKO cells to various 7-substituted tubercidins and other nucleoside analogs although tubercidin itself is a poor substrate for P1-type transporters. Individual nucleoside EC50s were similar for T. b. brucei, T. congolense, T. evansi and T. equiperdum but correlated less well with T. vivax. However, multiple nucleosides including 7-halogentubercidines displayed pEC50>7 for all species and, based on transporter and anti-parasite SAR analyses, we conclude that nucleoside chemotherapy for AAT is viable.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
International journal of molecular sciences - 24(2023), 4 vom: 05. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ungogo, Marzuq A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.02.2023 Date Revised 28.02.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/ijms24043144 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353406929 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353406929 | ||
| 003 | DE-627 | ||
| 005 | 20231226055921.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms24043144 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1177.xml |
| 035 | |a (DE-627)NLM353406929 | ||
| 035 | |a (NLM)36834557 | ||
| 035 | |a (PII)3144 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ungogo, Marzuq A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cloning and Characterization of Trypanosoma congolense and T. vivax Nucleoside Transporters Reveal the Potential of P1-Type Carriers for the Discovery of Broad-Spectrum Nucleoside-Based Therapeutics against Animal African Trypanosomiasis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.02.2023 | ||
| 500 | |a Date Revised 28.02.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a African Animal Trypanosomiasis (AAT), caused predominantly by Trypanosoma brucei brucei, T. vivax and T. congolense, is a fatal livestock disease throughout Sub-Saharan Africa. Treatment options are very limited and threatened by resistance. Tubercidin (7-deazaadenosine) analogs have shown activity against individual parasites but viable chemotherapy must be active against all three species. Divergence in sensitivity to nucleoside antimetabolites could be caused by differences in nucleoside transporters. Having previously characterized the T. brucei nucleoside carriers, we here report the functional expression and characterization of the main adenosine transporters of T. vivax (TvxNT3) and T. congolense (TcoAT1/NT10), in a Leishmania mexicana cell line ('SUPKO') lacking adenosine uptake. Both carriers were similar to the T. brucei P1-type transporters and bind adenosine mostly through interactions with N3, N7 and 3'-OH. Expression of TvxNT3 and TcoAT1 sensitized SUPKO cells to various 7-substituted tubercidins and other nucleoside analogs although tubercidin itself is a poor substrate for P1-type transporters. Individual nucleoside EC50s were similar for T. b. brucei, T. congolense, T. evansi and T. equiperdum but correlated less well with T. vivax. However, multiple nucleosides including 7-halogentubercidines displayed pEC50>7 for all species and, based on transporter and anti-parasite SAR analyses, we conclude that nucleoside chemotherapy for AAT is viable | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Trypanosoma congolense | |
| 650 | 4 | |a Trypanosoma vivax | |
| 650 | 4 | |a adenosine transporter | |
| 650 | 4 | |a animal trypanosomiasis | |
| 650 | 4 | |a nagana | |
| 650 | 4 | |a nucleoside antimetabolite | |
| 650 | 4 | |a nucleoside transporter | |
| 650 | 4 | |a tubercidin analog | |
| 650 | 7 | |a Nucleosides |2 NLM | |
| 650 | 7 | |a Tubercidin |2 NLM | |
| 650 | 7 | |a M351LCX45Y |2 NLM | |
| 650 | 7 | |a Adenosine |2 NLM | |
| 650 | 7 | |a K72T3FS567 |2 NLM | |
| 700 | 1 | |a Aldfer, Mustafa M |e verfasserin |4 aut | |
| 700 | 1 | |a Natto, Manal J |e verfasserin |4 aut | |
| 700 | 1 | |a Zhuang, Hainan |e verfasserin |4 aut | |
| 700 | 1 | |a Chisholm, Robyn |e verfasserin |4 aut | |
| 700 | 1 | |a Walsh, Katy |e verfasserin |4 aut | |
| 700 | 1 | |a McGee, MarieClaire |e verfasserin |4 aut | |
| 700 | 1 | |a Ilbeigi, Kayhan |e verfasserin |4 aut | |
| 700 | 1 | |a Asseri, Jamal Ibrahim |e verfasserin |4 aut | |
| 700 | 1 | |a Burchmore, Richard J S |e verfasserin |4 aut | |
| 700 | 1 | |a Caljon, Guy |e verfasserin |4 aut | |
| 700 | 1 | |a Van Calenbergh, Serge |e verfasserin |4 aut | |
| 700 | 1 | |a De Koning, Harry P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d 2008 |g 24(2023), 4 vom: 05. Feb. |w (DE-627)NLM185552161 |x 1422-0067 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:4 |g day:05 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijms24043144 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 4 |b 05 |c 02 | ||